Zhiwen Fu
- Oncology top 5%
- Molecular Biology
- Radiology, Nuclear Medicine and Imaging top 5%
- Immunology
- Pulmonary and Respiratory Medicine
- Topics
- HER2/EGFR in Cancer Research (6 papers)Pharmacovigilance and Adverse Drug Reactions (5 papers)Chronic Lymphocytic Leukemia Research (4 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Zhiwen Fu
38 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 699
- Molecular Biology 591
- Radiology, Nuclear Medicine and Imaging 433
- Immunology 166
- Pulmonary and Respiratory Medicine 155
Countries citing papers authored by Zhiwen Fu
This map shows the geographic impact of Zhiwen Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhiwen Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhiwen Fu more than expected).
Fields of papers citing papers by Zhiwen Fu
This network shows the impact of papers produced by Zhiwen Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhiwen Fu. The network helps show where Zhiwen Fu may publish in the future.
Co-authorship network of co-authors of Zhiwen Fu
This figure shows the co-authorship network connecting the top 25 collaborators of Zhiwen Fu. A scholar is included among the top collaborators of Zhiwen Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhiwen Fu. Zhiwen Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 4 | |
| 6 | 1 | |
| 7 | 1 | |
| 8 | 17 | |
| 9 | 14 | |
| 10 | 2 | |
| 11 | 7 | |
| 12 | 6 | |
| 13 | 8 | |
| 14 | 8 | |
| 15 | 24 | |
| 16 | Antibody drug conjugate: the “biological missile” for targeted cancer therapybreakdown → | 950 |
| 17 | 19 | |
| 18 | 16 | |
| 19 | 20 | |
| 20 | 26 |
About Zhiwen Fu
Zhiwen Fu is a scholar working on Toxicology, Complementary and alternative medicine and Oncology, having authored 45 papers that have together received 1.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Pharmacovigilance and Adverse Drug Reactions (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Oncology (699 citations), Radiology, Nuclear Medicine and Imaging (433 citations) and Cancer Research (143 citations). Zhiwen Fu has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Yu Zhang, Shijun Li, Shi Chen, Sifei Han, Chenggang Huang, Chen Shi, Shijun Li, Fen Chen, Kathy K. W. Au-Yeung and Liu Wang. Their work appears in journals such as Scientific Reports, Journal of Controlled Release and Small.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.